Oramed Pharmaceuticals
ORMP
30 hedge funds and large institutions have $2.36M invested in Oramed Pharmaceuticals in 2019 Q3 according to their latest regulatory filings, with 6 funds opening new positions, 6 increasing their positions, 5 reducing their positions, and 2 closing their positions.
644% more call options, than puts
Call options by funds: $357K | Put options by funds: $48K
200% more first-time investments, than exits
New positions opened: 6 | Existing positions closed: 2
20% more repeat investments, than reductions
Existing positions increased: 6 | Existing positions reduced: 5
15% more funds holding
Funds holding: 26 → 30 (+4)
0.46% less ownership
Funds ownership: 4.83% → 4.38% (-0.46%)
20% less capital invested
Capital invested by funds: $2.94M → $2.36M (-$578K)
100% less funds holding in top 10
Funds holding in top 10: 1 → 0 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Renaissance Technologies
New York
|
+$179K |
| 2 |
TRCT
Tower Research Capital (TRC)
New York
|
+$56.6K |
| 3 |
Millennium Management
New York
|
+$52.5K |
| 4 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$49.3K |
| 5 |
TI
Telemetry Investments
New York
|
+$33.3K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
SM
Sabby Management
Miami Beach,
Florida
|
-$563K |
| 2 |
Jane Street
New York
|
-$67K |
| 3 |
PAM
Panagora Asset Management
Boston,
Massachusetts
|
-$46K |
| 4 |
BlackRock
New York
|
-$8.87K |
| 5 |
Simplex Trading
Chicago,
Illinois
|
-$5.91K |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
|
SPIA
26
Steward Partners Investment Advisory
New York
| $3K | – | – | – |
|
|
JWA
27
JFS Wealth Advisors
Hermitage,
Pennsylvania
| $2K | – | – | – |
|
|
LTFS
28
Ladenburg Thalmann Financial Services
Miami,
Florida
| $2K | – | – | – |
|
|
GT
29
Glenmede Trust
Philadelphia,
Pennsylvania
| $63 | – | – | – |
|
|
PAM
30
Panagora Asset Management
Boston,
Massachusetts
| – | -$46K | -12,864 | Closed |
|
|
31
Simplex Trading
Chicago,
Illinois
| – | -$5.91K | -1,775 | Closed |
|
|
SFS
32
Sowell Financial Services
North Little Rock,
Arkansas
| – | +$426 | +128 | New |
|
ORMP Hedge Fund Activity: Q3 2019 in Review
30 of the 4,560 institutional investors tracked by Wall St. Rank reported a position in Oramed Pharmaceuticals (ORMP) for Q3 2019, worth a combined $2.36M — down 20% from $2.94M a quarter earlier.
Buyers outnumbered sellers: 6 funds opened new ORMP positions and 2 closed out — a net gain of 4 holders — while 6 added to existing stakes and 5 trimmed.
The largest buyer was Renaissance Technologies, adding an estimated $179K. The largest seller was Sabby Management, cutting an estimated $563K.
- 30 institutional investors held Oramed Pharmaceuticals (ORMP) as of Q3 2019, up from 26 in Q2 2019.
- Funds reported $2.36M of Oramed Pharmaceuticals stock for Q3 2019, down 20% quarter-over-quarter.
- 6 funds opened new Oramed Pharmaceuticals positions in Q3 2019 and 2 closed out, a net change of +4 holders.
- The largest Oramed Pharmaceuticals buyer in Q3 2019 was Renaissance Technologies, an estimated $179K added.
- The largest Oramed Pharmaceuticals seller in Q3 2019 was Sabby Management, an estimated $563K sold.
Based on aggregated 13F filings for Q3 2019.